SCHEMBL7713360

SCHEMBL7713360

CC1=C(N)Nc2cc(CN(Cc3c(F)cccc3Cl)C(=O)OC(C)(C)C)ccc2O1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.37
HTT P42858 2/20 0.33
POLB P06746 2/20 0.33
ABL1 P00519 1/20 0.33
RIN1 Q13671 1/20 0.33
MCOLN3 Q8TDD5 1/20 0.33
GAA P10253 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 1/20 0.33
SLC22A12 Q96S37 2/20 0.32
HDAC3 O15379 1/20 0.32
HDAC1 Q13547 1/20 0.32
HDAC2 Q92769 1/20 0.32
NCOR2 Q9Y618 1/20 0.32
MAPT P10636 2/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
MITF O75030 1/20 0.32
LMNA P02545 1/20 0.32
HPGD P15428 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7710867 0.87 ALDH1A1 (0.38) ALDH1A1HTTPOLBHDAC3HDAC1
SCHEMBL7704988 0.87 HDAC3 (0.36) ALDH1A1HTTPOLBHDAC3HDAC1
SCHEMBL7704902 0.86 RIPK1 (0.37) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL7711248 0.86 RIPK1 (0.37) ALDH1A1NPC1HDAC3HDAC1HDAC2
SCHEMBL7711458 0.86 HDAC3 (0.33) HDAC3HDAC1HDAC2NCOR2SMN1; SMN2
SCHEMBL7708353 0.85 GRM2 (0.37) ALDH1A1HTTHDAC3HDAC1HDAC2
SCHEMBL7704965 0.85 HDAC3 (0.36) ALDH1A1HTTPOLBGAAHDAC3
SCHEMBL7704910 0.84 HDAC1 (0.45) ALDH1A1HDAC3HDAC1HDAC2NCOR2
SCHEMBL7708189 0.83 HDAC3 (0.37) ALDH1A1POLBGAAHDAC3HDAC1
SCHEMBL7711366 0.83 HDAC1 (0.37) ALDH1A1HDAC3HDAC1HDAC2NCOR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed